Home > Insider Trading > Filing (0000950170-24-030482)

Filing Details

Accession Number:: 0000950170-24-030482
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-12 21:57:40
Reporting Period:: 2024-03-08

Accepted Time:: 2024-03-12 21:57:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818794	Dyne Therapeutics Inc.	DYN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1789545	William Richard Scalzo	1560 Trapelo Road Waltham MA 02451	Svp, Head Of Finance & Admin.	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-08	68,919	$5.54	190,874	No	4	M	Direct
Common Stock	Acquisiton	2024-03-08	17,333	$5.54	208,207	No	4	M	Direct
Common Stock	Disposition	2024-03-08	30,755	$25.31	177,452	No	4	S	Direct
Common Stock	Disposition	2024-03-08	55,208	$26.72	122,244	No	4	S	Direct
Common Stock	Disposition	2024-03-08	289	$27.33	121,955	No	4	S	Direct
Common Stock	Disposition	2024-03-11	1,082	$25.70	120,873	No	4	S	Direct
Common Stock	Disposition	2024-03-11	1,590	$24.99	119,283	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2024-03-08	68,919	$0.00	68,919	$5.54
Common Stock	Stock option (right to buy)	Disposition	2024-03-08	17,333	$0.00	17,333	$5.54

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,855		2030-07-30	No	4	M	Direct
0		2030-07-30	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.15, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive.
Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.50 to $26.09, inclusive.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.83 to $25.23, inclusive.
Includes 115,624 unvested RSUs.
The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments through July 31, 2024 provided that no shares shall vest prior to December 2, 2020.
The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.